CR8353A - Nuevas formas cristalinas de (2-(1-(3,5-bis-triflurometil-bencil-5-piridin-4-il-1h-(1,2,3) tria zol-4-il)-(2-clorofenil)-metanona - Google Patents

Nuevas formas cristalinas de (2-(1-(3,5-bis-triflurometil-bencil-5-piridin-4-il-1h-(1,2,3) tria zol-4-il)-(2-clorofenil)-metanona

Info

Publication number
CR8353A
CR8353A CR8353A CR8353A CR8353A CR 8353 A CR8353 A CR 8353A CR 8353 A CR8353 A CR 8353A CR 8353 A CR8353 A CR 8353A CR 8353 A CR8353 A CR 8353A
Authority
CR
Costa Rica
Prior art keywords
chlorophenyl
triflurometil
metanona
bencil
piridin
Prior art date
Application number
CR8353A
Other languages
English (en)
Inventor
Borghese Alfio
Scott Coffey David
Kaye Footman Pamela
Wayne Pedersen Steven
Marie Reutzel-Edens Susan
Lenyonga Tameze Shella
Timpe Carsten
Weber Carsten
Original Assignee
Eli Lilly And Company123456
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company123456 filed Critical Eli Lilly And Company123456
Publication of CR8353A publication Critical patent/CR8353A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una forma cristalina de {2- [1-(3-5-bistrifluorometilbnecil) - 5- piridin-4- il-1H - [1,2,3] triazol -4-il]- piridin- 3-il} -(2- clorofenil)- metanona, forma IV.
CR8353A 2003-10-24 2006-04-21 Nuevas formas cristalinas de (2-(1-(3,5-bis-triflurometil-bencil-5-piridin-4-il-1h-(1,2,3) tria zol-4-il)-(2-clorofenil)-metanona CR8353A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
CR8353A true CR8353A (es) 2006-06-06

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8353A CR8353A (es) 2003-10-24 2006-04-21 Nuevas formas cristalinas de (2-(1-(3,5-bis-triflurometil-bencil-5-piridin-4-il-1h-(1,2,3) tria zol-4-il)-(2-clorofenil)-metanona

Country Status (28)

Country Link
US (1) US7381826B2 (es)
JP (1) JP4959336B2 (es)
KR (1) KR100848407B1 (es)
CN (1) CN1863791B (es)
AR (1) AR046131A1 (es)
AT (1) ATE462700T1 (es)
AU (1) AU2004285855B8 (es)
BR (1) BRPI0415010B8 (es)
CA (1) CA2542140C (es)
CL (2) CL2009001311A1 (es)
CR (1) CR8353A (es)
DE (1) DE602004026333D1 (es)
DK (1) DK1675846T3 (es)
EA (1) EA008881B1 (es)
EC (1) ECSP066517A (es)
ES (1) ES2340772T3 (es)
HR (1) HRP20100207T1 (es)
IL (1) IL174926A0 (es)
MA (1) MA28329A1 (es)
MY (1) MY157375A (es)
NO (1) NO335090B1 (es)
NZ (2) NZ580480A (es)
PE (1) PE20050481A1 (es)
PT (1) PT1675846E (es)
TW (1) TW200524906A (es)
UA (1) UA82901C2 (es)
WO (1) WO2005042515A1 (es)
ZA (1) ZA200603234B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079600A1 (en) * 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
HRP20250615T1 (hr) 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
US20210228555A1 (en) 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2021173641A1 (en) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2025542424A (ja) 2022-12-21 2025-12-25 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる処置の方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ATE333879T1 (de) * 1996-10-07 2006-08-15 Merck Sharp & Dohme Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
JP2003531103A (ja) * 1999-08-12 2003-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＪＵＮＮ−末端キナーゼ（ＪＮＫ）および他のタンパク質キナーゼの阻害剤
AU1343901A (en) 1999-10-29 2001-05-14 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
CN1863791A (zh) 2006-11-15
AU2004285855A1 (en) 2005-05-12
ECSP066517A (es) 2006-10-10
CL2009001311A1 (es) 2009-10-02
HRP20100207T1 (hr) 2010-05-31
IL174926A0 (en) 2006-08-20
EA200600829A1 (ru) 2006-08-25
AU2004285855B2 (en) 2010-12-23
ES2340772T3 (es) 2010-06-09
CA2542140A1 (en) 2005-05-12
NZ545917A (en) 2009-11-27
JP4959336B2 (ja) 2012-06-20
UA82901C2 (en) 2008-05-26
EA008881B1 (ru) 2007-08-31
JP2007509143A (ja) 2007-04-12
KR20060061388A (ko) 2006-06-07
BRPI0415010A (pt) 2006-11-07
US20070078166A1 (en) 2007-04-05
KR100848407B1 (ko) 2008-07-28
BRPI0415010B8 (pt) 2021-05-25
CN1863791B (zh) 2011-12-07
BRPI0415010A8 (pt) 2018-05-08
NO335090B1 (no) 2014-09-08
US7381826B2 (en) 2008-06-03
NZ580480A (en) 2010-02-26
DE602004026333D1 (de) 2010-05-12
PT1675846E (pt) 2010-04-20
AU2004285855B8 (en) 2011-04-28
MY157375A (en) 2016-06-15
DK1675846T3 (da) 2010-05-31
CL2009001310A1 (es) 2009-12-04
WO2005042515A1 (en) 2005-05-12
BRPI0415010B1 (pt) 2019-07-09
TW200524906A (en) 2005-08-01
MA28329A1 (fr) 2006-12-01
ZA200603234B (en) 2007-07-25
NO20062371L (no) 2006-05-24
PE20050481A1 (es) 2005-09-20
AR046131A1 (es) 2005-11-23
CA2542140C (en) 2012-05-29
ATE462700T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
CR8353A (es) Nuevas formas cristalinas de (2-(1-(3,5-bis-triflurometil-bencil-5-piridin-4-il-1h-(1,2,3) tria zol-4-il)-(2-clorofenil)-metanona
LTPA2016037I1 (lt) Nauji heterocikliniai junginiai, veiksmingi kaip beta-laktamazės slopikliai
CO5550395A2 (es) Antranilamidas artropodicidas
DE60322920D1 (de) Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
AR052132A1 (es) Polimorfos de {5-[3-(4,6-difloruro-1h- benzoimidazol-2-il)-1h-indazol-5-il]-4- metil-piridin-3- ilmetil}-etil- amina
NO20032022D0 (no) Hyrdraulisk brönnverktöy
AR047541A1 (es) Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
NO20032315L (no) 4-(bifenylkarbonylamino)piperidinderivater som MTP- inhibitorer
ITMI20032436A1 (it) Apparato di controllo di una valvola idraulica per la tenuta di carico.
ITTO20050150A1 (it) Circuito idraulico per una macchina per l'edilizia.
ITMI20031323A1 (it) Dispositivo di comando della valvola di scarico di una cassetta di risciacquo.
IT1319906B1 (it) Maniglia per una portiera di un veicolo.
CR7962A (es) Clorhidrato de 1-(4-(2-piperidiniletoxi) Fenoxi)-2-(-4Metanosulfonifenil)-6-Hidroxinaftaleno Cristalino no solvatado
NO20034505D0 (no) Bredspektret 2-(substituert-amino)-benzoxasolsulfonamid HIV proteasehemmere
AU2001271418A1 (en) 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
ITTV20030142A1 (it) Struttura di pannello, particolarmente per l'isolamento di una caldana.
MX252778B (es) Modificacion cristalina ii de la 2-[2 -(1-cloro- ciclopropil)- 3-(2-clorofenil)- 2 hidroxi- propil]-2, 4-dihidro -3h-1, 2, 4-triazol -3-tiona.
DE60317354D1 (de) Neue klebemittel, die diacetale enthalten
ITBZ20040001A1 (it) Procedimento per il funzionamento di una trasmissione a frizione come pure trasmissione a frizione.
AU2003269483A1 (en) Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
HK1092475A (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
ATE366576T1 (de) Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
ITTE20030005A1 (it) Procedimento per la realizzazione di una forma
ITLU20020014A1 (it) Soletto termoformato per una duplice applicazione

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)